BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Leowattana W, Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol 2022; 28(28): 3608-3619 [PMID: PMC9372813 DOI: 10.3748/wjg.v28.i28.3608]
URL: https://www.wjgnet.com/1007-9327/full/v28/i28/3608.htm
Number Citing Articles
1
Georges Jourdi, Jean-Sébastien Hulot, Pascale Gaussem. An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks?Expert Opinion on Drug Metabolism & Toxicology 2024; 20(8): 749 doi: 10.1080/17425255.2024.2378888
2
Xinxu Zhou, Hui Duan, Qian Li, Qiong Wang, Xiaobin Sun. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: a systematic review and meta-analysisScandinavian Journal of Gastroenterology 2024; 59(7): 788 doi: 10.1080/00365521.2024.2349638
3
ChaoRong Bian, Ping Shen, YunPeng Zang, Wen Liu, Peng Zhou. Vonoprazan Fumarate: A Promising Therapeutic Option for the Rapid Relief of Laryngopharyngeal Reflux DiseaseJournal of Voice 2025;  doi: 10.1016/j.jvoice.2024.12.031
4
Piotr Kucharczyk, Karolina Anna Parzęcka, Michał Jakub Symulewicz, Weronika Zań, Kinga Szczepanik, Olaf Domaradzki, Bartłomiej Kusy, Mateusz Michalak, Marta Stolińska. Innovative therapeutic strategies in the treatment of gastroesophageal reflux disease (GERD): A review of progress and perspectivesWiadomości Lekarskie 2024; 77(6): 1271 doi: 10.36740/WLek202406124
5
Mujtaba Alrayah, Rajab Alzahrani, Mohammed A Alghamdi, Kholoud M Alghamdi, Faisal F Almutairi, Anwar A Alghamdi, Raghad A Alzahrani, Taif A Bajaber, Tahani F Alanazi, Haya A Alnafisah. Assessment of the Current Knowledge and Practice of General Practitioners Towards Laryngopharyngeal Reflux in Saudi ArabiaCureus 2023;  doi: 10.7759/cureus.38043
6
M.A. Valdovinos Díaz, M. Amieva-Balmori, R. Carmona-Sánchez, E. Coss-Adame, O. Gómez-Escudero, M. González-Martínez, F. Huerta-Iga, E. Morel-Cerda, J.M. Remes-Troche, J.L. Tamayo-de la Cuesta, G. Torres-Villalobos, L.R. Valdovinos-García, G. Vázquez-Elizondo, A.S. Villar-Chávez, J.A. Arenas-Martínez. Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de GastroenterologíaRevista de Gastroenterología de México (English Edition) 2024; 89(1): 121 doi: 10.1016/j.rgmxen.2023.12.002
7
阳 高. Advances in the Treatment of Gastroesophageal Reflux DiseaseAdvances in Clinical Medicine 2024; 14(05): 1790 doi: 10.12677/acm.2024.1451617
8
Angela Tietto, Sofia Faggin, Carmelo Scarpignato, Edoardo Vincenzo Savarino, Maria Cecilia Giron. Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux diseaseExpert Opinion on Drug Metabolism & Toxicology 2025; 21(1): 53 doi: 10.1080/17425255.2024.2397433
9
E. A. Ortenberg, M. V. Lyapina, E. F. Dorodnyeva. Competitive proton pump inhibitors - status and Prospects of useExperimental and Clinical Gastroenterology 2023; (4): 86 doi: 10.31146/1682-8658-ecg-212-4-86-92
10
Jiten P. Kothadia, Colin W. Howden. Potassium-Competitive Acid Blockers for the Treatment of Gastroesophageal Reflux DiseaseForegut: The Journal of the American Foregut Society 2024; 4(1): 7 doi: 10.1177/26345161231181357
11
岚 卿. Progress of Potassium-Competitive Acid Blocker Tegoprazan in the Treatment of Acid-Related DiseasesAdvances in Clinical Medicine 2024; 14(08): 117 doi: 10.12677/acm.2024.1482189
12
Eunsol Yang, Inyoung Hwang, Sang Chun Ji, John Kim, SeungHwan Lee. Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteersCPT: Pharmacometrics & Systems Pharmacology 2024; 13(12): 2150 doi: 10.1002/psp4.13228
13
S. V. Tikhonov, E. N. Kareva, S. Yu. Serebrova, G. F. Vasilenko, M. K. Vasilyeva, S. A. Makhortova, N. V. Pavlova. New achievements of pharmacology for practical medicine in prevention and therapy of acid-dependent diseasesMeditsinskiy sovet = Medical Council 2023; (8): 33 doi: 10.21518/ms2023-133
14
Jeremy Klein, Robert T. Kavitt. Gastroesophageal Reflux Disease2023; : 61 doi: 10.1007/978-3-031-48241-0_8
15
Sergey M Kotelevets. Risks of anti-<i>Helicobacter</i> therapy and long-term therapy with antisecretory drugsWorld Journal of Gastroenterology 2025; 31(4): 101933 doi: 10.3748/wjg.v31.i4.101933
16
M.A. Valdovinos-Diaz, M. Amieva-Balmori, R. Carmona-Sánchez, E. Coss-Adame, O. Gómez-Escudero, M. González-Martínez, F. Huerta-Iga, E. Morel-Cerda, J.M. Remes-Troche, J.L. Tamayo-de la Cuesta, G. Torres-Villalobos, L.R. Valdovinos-García, G. Vázquez-Elizondo, A.S. Villar-Chávez, J.S. Arenas-Martínez. Recomendaciones de buena práctica clínica en el diagnóstico y tratamiento de la enfermedad por reflujo gastroesofágico. Revisión por expertos de la Asociación Mexicana de GastroenterologíaRevista de Gastroenterología de México 2024; 89(1): 121 doi: 10.1016/j.rgmx.2023.12.002
17
Seo Yeon Kim, Jung-Ho Yoon, Da Hyun Jung, Ga Hee Kim, Chul Hoon Kim, Sang Kil Lee. Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/Caspase-1/GSDMD pyroptotic pathwayFrontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1410904
18
Shupeng Zou, Mengling Ouyang, Qian Cheng, Xuan Shi, Minghui Sun. Acid‐suppressive drugs: A systematic review and network meta‐analysis of their nocturnal acid‐inhibitory effectPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2024; 44(2): 171 doi: 10.1002/phar.2899
19
Su Il Kim, Young Chan Lee, Wonjae Cha, Ah Ra Jung, Jeon Yeob Jang, Jeong-Seok Choi, Dong Kun Lee, Hwan Ho Lee, Min Su Kwon, Yoon Se Lee, Young-Gyu Eun. Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trialEuropean Archives of Oto-Rhino-Laryngology 2024; 281(11): 5873 doi: 10.1007/s00405-024-08877-6